← Back to Search

Telemedicine for Substance Use Disorders and HIV (HEAT Trial)

Waitlist Available
Led By Ellen F Eaton, MD, MSPH
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 1 month, 2 months, 3 months
Awards & highlights


"This trial aims to address the increasing rates of substance use disorders and infectious diseases, such as HIV and hepatitis C, in rural parts of the U.S. where healthcare resources are limited. The study will

Who is the study for?
The HEAT Program is for individuals with substance use disorders, including opioid and stimulant use, who may also be living with or at risk for HIV. It's particularly focused on those in rural areas of the U.S. South where healthcare access is limited due to systemic issues like racism and lack of public health infrastructure.Check my eligibility
What is being tested?
This trial is exploring how telemedicine can help people with substance use disorders receive better care, especially when they have or are at risk for HIV. The study compares standard in-person care to remote care via telemedicine to see if it improves access and outcomes.See study design
What are the potential side effects?
Since this trial involves service delivery methods (standard of care vs. telemedicine), there aren't direct side effects like you'd expect from a drug trial. However, participants might experience technical difficulties or feel less satisfied with remote interactions compared to face-to-face visits.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month, 2 months, 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month, 2 months, 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of participants who have a follow-up healthcare visit

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients living with HIV and substance useExperimental Treatment2 Interventions
Patients living with HIV and substance use, aged 18 and over. These participants are receiving services at HIV clinics in Alabama and must have reported opioid and/or stimulant misuse.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,599 Previous Clinical Trials
2,287,890 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,503 Previous Clinical Trials
2,625,553 Total Patients Enrolled
Ellen F Eaton, MD, MSPHPrincipal InvestigatorUniversity of Alabama at Birmingham
~20 spots leftby Jun 2029